Malignant pleural mesothelioma (MPM) is the most common type (about 80% reviewed in [@B18]) of malignant mesothelioma, a rapidly fatal and highly resilient tumor arising in the mesothelium, a tissue of mesodermal origins which covers many of the important internal organs (reviewed in ([@B39]). This cancer is mostly associated with exposure to asbestos (reviewed in Felley-Bosco and MacFarlane 2018).

Few years ago, we and others reported about hedgehog (Hh) signaling in a subset of MPM patients ([@B33]; [@B41]; [@B24]). We briefly discuss here whether, taking into account recent knowledge, it would be worth to consider these observations for mesothelioma therapy. We first consider data obtained using high throughput mesothelioma profiling studies ([@B2]; [@B12]), then we mention the caveats about successful hedgehog inhibition therapy in cancer (reviewed in Curran 2018) and finally we highlight novel aspects of hedgehog signaling in the context of immune signaling in cancer. Information about Hh signaling expression in cancers other than mesothelioma can be found in some recent reviews ([@B38]; [@B26]; [@B29];).

Canonical Hh core signaling include hedgehog ligands (sonic hedgehog, Shh; desert hedgehog, Dhh; indian hedgehog, Ihh) (reviewed in [@B28]) which activate the G protein-coupled receptor Smoothened (Smo), upon binding to the transmembrane receptor Patched (Ptch) removing its inhibitory effect. Activation of Smo then leads to nuclear translocation of the Glioma associated protein (Gli) family of transcription factors and induction of Hh target genes such as *Gli1, Ptch*1 and Hedgehog interacting protein (*Hhip*). The latter competes with Ptch by binding to Hh ligands ([@B3]), while cell-adhesion-molecule-related/downregulated by oncogenes (Cdon), bioregional Cdon-binding protein (Boc), and Growth Arrest Specific 1 (Gas1) positively regulate Hh signaling. Gli protein levels and activities are primarily regulated by Suppressor of Fused (Sufu) which is a negative regulator of mammalian Hh signaling ([@B4]; [@B36]).

While the Hh signaling pathway is necessary for embryonic mesothelial development ([@B7]) it is inactive in mesothelium ([@B33]). We were the first to show *SHH* gene expression in human MPM tumor tissues along with increased expression levels of *HHIP* and *GLI1* ([@B33]). High levels of *GLI-1* expression is significantly associated with worst overall survival in two independent cohorts of patients \[([@B33]) and analysis of mesothelioma TCGA (<https://portal.gdc.cancer.gov/projects/TCGA-MESO>) data using Progene2 ([@B10])\]. In a recent high-throughput multi-omics analysis ([@B2]), Hh signaling expression was enriched in sarcomatoid histotype, which is generally associated with worst overall survival. We also observed activation of Hh signaling during mesothelioma development in mice exposed to asbestos ([@B30]). Interestingly, a recent pan-cancer analysis ([@B6]) revealed that not only *GLI-1* (p = 0.019584614) but also *GLI-2* (p = 0.035063475) and *SHH* (p = 0.003447888) high expression have prognostic value in mesothelioma TCGA. Intriguingly, such correlation was not observed ([@B6]) by analyzing two other datasets, where expression was based on array data instead of RNA-seq. The reasons for the discrepancy are not straightforward. However, in all datasets bad prognosis was associated with epithelial to mesenchymal transition and stemness.

Oncoprint analysis ([www.cBioportal.org](www.cBioportal.org)) of TCGA data ([**Figure 1A**](#f1){ref-type="fig"}) shows that few mesothelioma patients bear *PTCH1* truncation mutations or *SUFU* deep deletions and there is a statistically significant co-occurrence between alterations of several components of Hh signaling ([**Figure 1B**](#f1){ref-type="fig"}). Interestingly however, there is no strict correlation with ligands expression and the ligand with the highest differential level is *DHH*. Mutations in human and murine mesothelioma cell lines has also been reported ([@B21]) ([@B35]).

![Hedgehog signaling in TCGA mesothelioma samples. "Oncoprint" analysis performed using cBioportal ([www.cBioportal.org](www.cBioportal.org)) of Hh components **(A)** and co-occurrence alterations statistically significant **(B)**.](fgene-10-01121-g001){#f1}

As recently pointed out (Curran 2018), it has been not possible to maintain Hh signaling when primary tumors are grown in the presence of serum. However, we were able to culture primary human MPM, in 3% oxygen, in the absence of serum, but in the presence of their own conditioned medium plus specific growth factors and, in some of them, we showed an active Hh signaling ([@B33]). In these conditions we could observe ([@B9]) the presence of primary cilia, a non-motile flagellar-like organelle present on growth-arrested cells ([@B32]) where Hh signaling occurs. This is possibly linked to the fact that about 35% of the cells grown in these conditions are quiescent ([@B31]), contrary to what is observed in cells cultured in the presence of serum. Giving the fact that in mesothelioma there is a considerable number of quiescent cells, since median cell-cycling marker Ki67 (also called MIB1) staining is 10% ([@B13]), an additional advantage of these culture conditions is to better resemble to tumors. Interestingly, DHH is the ligand whose expression is maintained in these conditions in several human and rodent mesothelioma models ([@B33]) ([@B24]). The reason for a differential expression of *DHH* in mesothelioma is not clear, especially because it is mostly associated with testis ([@B1]) and Schwann cell ([@B27]) development. An intriguing recent observation is that DHH positively regulates the differentiation from common myeloid progenitor (CMP) to granulocyte/macrophage progenitor and decreases the differentiation from CMP to megakaryocyte/erythrocyte progenitor ([@B16]). Are DHH producing mesothelioma cells influencing hematopoietic cells in the microenvironment?

Consistent with caveats recently discussed (Curran, 2018), it seems that Hh activation signature is not always associated with mutation in driver genes in mesothelioma although there are few patients with Hh driver mutations. Some Hh signature might be reflecting stromal activity. Pre-clinical studies have shown a moderate effect on tumor reduction accompanied by tumoral decrease of Hh-activation after treatment with Smo antagonists of tumor-bearing immunodeficient mice ([@B33]), while in another model in immunocompetent rats ([@B24]) the tumor decreasing effect was associated with a marked effect on tumor stroma.

Patients with *PTCH1* driver mutations should respond to Smo inhibitors. The latter have been tested only in three unselected mesothelioma patients and no response was observed ([@B23]). As for other targeted therapy, there is a need for proper predictive biomarkers. In medulloblastoma, another cancer where a subgroup of patients shows Hh activation, a five-gene expression signature was used to select patients who received Smo inhibitor and 66% showed objective responses ([@B34]). In a more recent study, this Hh signature showed that the five responders and three patients with stable disease had Hh-activated tumors, while two patients with activated Hh and 50 patient with an Hh-negative signature did not respond to Smo inhibition ([@B14]). It is still not known whether this gene signature would be the same in mesothelioma, and it is not sure whether energy will be invested in tackling Hh signaling as therapeutic strategy in few patients, in view of the more frequent signaling pathways altered in this disease ([@B2]; [@B12]).

Patients with Hh-ligand independent mutations may benefit from alternative therapeutic strategies. Several studies reported that Gli1 inhibition, either by agents such as arsenic trioxide, which prevents Gli2 localization to primary cilia ([@B15]) or GANT61, which prevents Gli1-DNA binding in living cells ([@B17]), resulted in growth arrest and induction of cell death in MPM cell *in vitro* ([@B19]; [@B40]; [@B20]).

Further complexity is added by the recent observation that Shh produced by tumor associated astrocytes promote medullobastoma growth by increasing nestin expression independently of Gli-1 ([@B22]). Nestin is a biomarker of epithelial to mesenchymal transition in MPM and high expression levels are associated with worst outcome ([@B37]), but it is not clear whether it is associated with any Hh signaling in MPM.

Finally, there is an aspect of Hh signaling which is worth mentioning in the context of immunotherapy, which is changing the handling of cancer patients, including MPM patients. Hh ligands (including DHH) produced by tumor cells lead to Gli-1 mediated "M2-polarization" of macrophages ([@B11]) which is associated with immunosuppression and pro-tumorigenic activity. This additional cross talk between tumor cells and stroma is therefore of potential importance in a cancer characterized by abundant "M2-polarized" macrophages (Minnema-Luiting et al., 2018).

Dr. Curran mentioned (Curran 2018) that the difference between Hh inhibitor concentration leading to the decrease of hedgehog reporter activity in mouse fibroblast and the concentration necessary to inhibit tumor cell growth is indicating reasons for clinical failure in the treatment of cancer patients using Hh inhibition.

Although agreeing with that caveat, based on our own and recent data in multi-omics studies, our opinion is that it is likely that Hh signaling functions as a pro-tumorigenic signal in some MPM. Indeed, both Hh ligand-dependent and ligand-independent effects promote MPM cell growth in experimental models and high through-put analysis of MPM patients shows that the Hh pathway is active in a subset of patients. It is up to the mesothelioma research community to coordinate efforts to further investigate this aspect.
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